Abstract
Background: Hemorrhagic shock (HS) is the most common cause of potentially preventable death after traumatic injury. Acute liver injury is an important manifestation of HS. Apoptosis plays an important role in liver injury. Farnesoid X receptor (FXR) can alleviate liver injury. This study aimed to examine the effects of ursodeoxycholic acid (UDCA) on hepatocyte apoptosis in HS and its relationship with the FXR pathway.
Methods: Mice were randomly divided into 4 groups: sham group, HS group, HS + UDCA group, and FXR (-) + HS + UDCA group. There were 6 mice in each group. As to the model of HS, MAP of 40 ± 5 mmHg was maintained for 1 hour. As to UDCA intervention, UDCA (300mg/kg) was given nasally. Real-time RT-PCR and Western blotting were used to detect changes in the expression level of Caspase-3, Bax, LC3Ⅰ, LC3Ⅱ, Bcl-2, and Beclin-1 in the liver. TUNEL assay was used to detect changes in hepatocyte apoptosis.
Results: The expression level of Caspase-3 and Bax in the liver decreased significantly after treatment with UDCA under HS conditions. The expression level of LC3Ⅰ, LC3Ⅱ, Bcl-2, and Beclin-1 in the liver increased significantly after treatment with UDCA under HS conditions. TUNEL positive percentage of liver decreased significantly after treatment with UDCA under HS conditions. In the case of FXR (-), the influence of UDCA was inhibited.
Conclusion: These results indicated that UDCA could reduce hepatocyte apoptosis during HS through the FXR pathway.
Keywords: Ursodeoxycholic acid, hepatocyte apoptosis, farnesoid X receptor, hemorrhagic shock, liver injury, trauma.
[http://dx.doi.org/10.1097/01.ta.0000199961.02677.19] [PMID: 16763478]
[http://dx.doi.org/10.1097/00005373-199502000-00006] [PMID: 7869433]
[http://dx.doi.org/10.1016/j.gastrohep.2016.03.007] [PMID: 27112800]
[http://dx.doi.org/10.1111/jcmm.15617] [PMID: 32691975]
[http://dx.doi.org/10.3390/ijms18051018] [PMID: 28486401]
[http://dx.doi.org/10.1111/hepr.12783]
[http://dx.doi.org/10.1053/jhep.2002.36088] [PMID: 12198643]
[http://dx.doi.org/10.2174/1566524015666150114110551] [PMID: 25601465]
[http://dx.doi.org/10.1016/j.celrep.2018.07.068] [PMID: 30208322]
[http://dx.doi.org/10.1002/hep4.1256] [PMID: 30411084]
[http://dx.doi.org/10.1016/j.ebiom.2018.10.028] [PMID: 30337250]
[http://dx.doi.org/10.1186/s12950-014-0030-7] [PMID: 25309129]
[http://dx.doi.org/10.1155/2017/1763292] [PMID: 28127564]
[http://dx.doi.org/10.1089/jop.2010.0012] [PMID: 20565307]
[http://dx.doi.org/10.1111/j.1745-7270.2005.00108.x] [PMID: 16270150]
[http://dx.doi.org/10.1007/s00604-018-2980-6] [PMID: 30159750]
[http://dx.doi.org/10.4070/kcj.2019.0107] [PMID: 31845557]
[http://dx.doi.org/10.1124/jpet.120.000092] [PMID: 32759272]
[http://dx.doi.org/10.1002/jcla.23102] [PMID: 31743516]
[http://dx.doi.org/10.1016/j.bbrc.2017.06.190] [PMID: 28676391]
[http://dx.doi.org/10.1038/s41419-020-2476-2] [PMID: 32332857]
[http://dx.doi.org/10.1146/annurev-immunol-042617-053253] [PMID: 29144836]
[http://dx.doi.org/10.15252/embj.201899430] [PMID: 30617086]
[http://dx.doi.org/10.1101/pdb.prot087221] [PMID: 27698233]
[http://dx.doi.org/10.1002/hep.25918] [PMID: 22730081]
[http://dx.doi.org/10.2131/jts.40.501] [PMID: 26165647]
[http://dx.doi.org/10.1016/j.ejphar.2020.173653] [PMID: 33068587]
[http://dx.doi.org/10.1016/j.bbamcr.2013.05.006] [PMID: 23680185]